

March 23-24, 2026 | San Diego, CA | Hilton San Diego Bayfront + Virtual



Inaugural

HERS

Health Executive & Research Summit

EMPOWERING WOMEN'S HEALTH, CAPITAL & CARE

ONE EVENT, THREE COMPREHENSIVE PROGRAMS:

Women's Health Venture and Innovation

Driving Innovation in
Women's Health MedTech,
Therapeutics, Diagnostics,
and Digital Health

Women's Health: Drug Discovery to Novel Therapies

Where Innovation
Meets Impact

The Future of Women's Healthcare

Redefining Care,
Revolutionizing Health
Outcomes for Women

FEATURED SPEAKERS:



Michael Annichine
CEO, Magee-Womens
Research Institute &
Foundation



Joanne Armstrong
Vice President &
Chief Medical Officer,
Women's Health &
Genomics, CVS Health



Sandra Culbertson
Chair, Women's &
Children's Institute,
Geisinger



Jill Foley
Chair, Women's Health
Service Line,
Sutter Health



**Anula Jayasuriya,
MD, PhD**
Co-Founder & Managing
Partner, Kidron Capital



Jessica Karr
General Partner,
Coyote Ventures



Janet Pregler, MD
Professor, UCLA; Director,
Iris Cantor-UCLA
Women's Health Center



Wendy Young, PhD
Scientific Advisor &
Board Director; Former
SVP, Genentech



Alice Zheng, MD
Partner,
Foreground Capital

Corporate Support
Sponsor:



#HERSummit
www.HERSusa.com

REGISTER BY FEBRUARY 27
AND SAVE \$100

HERS: Health Executive and Research Summit

The Urgent Need to Transform Women's Health

Women's health has long been an underserved and underfunded area of medicine, despite women comprising over half the global population. From historically excluded clinical trials to persistent diagnostic gaps and limited funding for female-specific conditions, the need to transform women's health care is urgent and the opportunity is immense.

Introducing HERS: Health Executive and Research Summit

For more than 30 years, Cambridge Healthtech Institute (CHI) has been at the forefront of convening leaders across the life sciences, diagnostics, and medical technology sectors. We are proud to launch HERS: Health Executive and Research Summit, a groundbreaking event dedicated to advancing innovation in women's health.

Join us at HERS to:

- **Track the Shift from Investment to Research to Results in Women's Health**

From next-gen diagnostics and AI-powered screening tools to targeted therapies, new drug targets and patient-centric wearables, you will explore cutting-edge research and real-world solutions designed to close clinical gaps and improve outcomes across the women's health continuum.

- **Connect Across the Ecosystem**

Meet investors, entrepreneurs, scientists, healthcare leaders, clinicians, and advocates who are driving change across the women's health landscape. Whether you're developing a new drug, building a startup, funding the future, or implementing change on the front lines, HERS is the place to build lasting connections.

- **Demystify the Funding & Commercialization Landscape**

Get candid insights from scientists-turned-founders, venture capitalists, innovators, and market access strategists on what it takes to bring women's health solutions to market from navigating reimbursement hurdles to seizing growth opportunities in a rapidly evolving investment climate.

- **Drive the Future of Women's Health**

Join the movement to correct decades of underinvestment and underrepresentation in women's health. You will walk away with actionable insights and a clearer path to scale your work and impact. Furthermore, you will connect with changemakers across science, business, and policy to explore bold solutions in diagnostics, therapeutics, and healthcare delivery.



A Curated Lineup of Acclaimed Speakers and Leaders



Katherine Andersen
Head of US Life Science & Healthcare,
HSBC Innovation Bank



Joanne Armstrong
Vice President & Chief Medical Officer, Women's Health & Genomics, CVS Health



Katie Baca-Motes
CEO & Co-Founder, GSD Healthcare



Ami Bhatt
Chief Innovation Officer, American College of Cardiology



Trish Costello
CEO & Founder, Portfolia; CEO Emeritus, Kauffman Fellows



Sandra Culbertson
Chair, Women's & Children's Institute, Geisinger



Ukachi Emeruwa
Assistant Professor, Women's Reproductive Health Research Scholar, UC San Diego Health



Jessica J. Federer
Board Member, Angelini Ventures



Marlena Fejzo, PhD
Assistant Professor, Center for Genetic Epidemiology, University of Southern California



Tanaz Ferzandi
Vice Chief of Staff & Service Line Chief, Obstetrics & Gynecology, Keck Hospital of USC



Jill Foley
Chair, Women's Health Service Line, Sutter Health



Angelika Fretzen, PhD, MBA
COO & Technology Translation Director, Wyss Institute, Harvard University



Elizabeth Garner, MD, MPH
CEO, SeNa Therapeutics



Nada Hanafi
Co-Founder Women's Health Advocates



Carol Huffman
Vice President, Clinical Innovation & Implementation, MVP Health Care



Priyanka Jain
Co-Founder & CEO, Evvy



Anula Jayasuriya, MD, PhD
Co-Founder & Managing Partner, Kidron Capital



Petrina Kamyra, PhD
Global Head of AI Platforms & Vice President, Insilico Medicine; President, Insilico Medicine Canada



Jessica Karr
General Partner, Coyote Ventures



Seema Kumar
CEO, Cure



Michael Liebman, PhD
Managing Director, IPQ Analytics



Jason Melillo
Vice President, Women's Clinical Services, OhioHealth



Jodi Neuhauser
Founder & CEO, In Women's Health



Andrea Olariu, MD, PhD
CEO, Medicines360



Lisa Pellerin
System Vice President, Women's Services, Ochsner Health



Aritro Sen, PhD
Co-Founder & CSO, Maip Therapeutics, Inc.



Kristina Stuecher
Vice President, OhioHealth, Women's Center, OhioHealth



Sarah Temkin, MD
Senior Director, Early Detection, American Cancer Society



Gina Wang, PhD
Senior Director & Distinguished Scientist, Genentech, Inc.



Alice Zheng, MD
Partner, Foreground Capital

Women's Health Venture and Innovation

Driving Innovation in Women's Health MedTech, Therapeutics, Diagnostics, and Digital Health



March 23-24, 2026

MONDAY, MARCH 23

7:30 am Registration Open and Morning Coffee

PLENARY KEYNOTE SESSION

8:30 Organizer's Welcome Remarks

Jason Green, Senior Conference Director, Cambridge Healthtech Institute

8:35 Chairperson's Remarks

Jen Radin, Principal, Deloitte

8:40 Keynote Introduction (Sponsorship Opportunity Available)

8:45 PANEL DISCUSSION: Fueling Women's Health with Science, Technology, Capital & Care

Moderator: Jen Radin, Principal, Deloitte

Women's health has gained momentum, but we need to capitalize on it in a meaningful way to make long-term, scalable, and sustainable progress. This keynote panel brings together the key stakeholders in venture, R&D, and healthcare to provide insights into the leading opportunities and challenges facing the field.

Panelists:

Michael Annichine, CEO, Magee-Womens Research Institute & Foundation

Cathy Friedman, Executive Venture Partner, Google Ventures

Jodi Neuhauser, CEO & Founder, 51&

Kathryn Rexrode, MD, MPH, Chief Academic Officer & Chief, Division of Women's Health, Brigham & Women's Hospital

Alice Zheng, MD, Partner, Foreground Capital

9:45 Grand Opening Coffee Break in the Exhibit Hall

WOMEN'S HEALTH INVESTMENT LANDSCAPE: UPDATE ON GROWTH TRENDS AND FUNDING OPPORTUNITIES

10:25 Chairperson's Remarks

Jessica J. Federer, Board Member, Angelini Ventures

10:30 Women's Health Venture and Innovation: Overview of Current Funds, Exits, and Investments

Jessica J. Federer, Board Member, Angelini Ventures

10:45 PANEL DISCUSSION: Women's Health Investment Landscape: Updating Growth Trends and Funding Opportunities

Moderator: Jessica J. Federer, Board Member, Angelini Ventures

Gain insights into the evolving women's health investment landscape as experts share current funding trends, emerging market opportunities, and areas attracting investor attention. This panel will explore growth drivers, deal activity, and strategies for advancing innovation and capital flow in one of healthcare's most dynamic and rapidly expanding sectors.

Panelists:

Katherine Andersen, Head of US Life Science & Healthcare, HSBC Innovation Banking

Jessica Karr, General Partner, Coyote Ventures

Eric Schaefer, Senior Director, Portfolio Strategy & Mission Investment, March of Dimes

Tracy Warren, Senior Managing Director, Go Red for Women Fund, AHA Ventures, American Heart Association

Alice Zheng, MD, Partner, Foreground Capital

11:30 Sponsored Presentation (Opportunity Available)

12:00 pm Transition to Lunch

12:10 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:40 Session Break

1:30 Chairperson's Remarks

Katherine Andersen, Head of US Life Science & Healthcare, HSBC Innovation Banking

1:35 PANEL DISCUSSION: Building and Scaling Women's Health Ventures: Funding, Partnerships, and Exit Pathways

Moderator: Katherine Andersen, Head of US Life Science & Healthcare, HSBC Innovation Banking

Women's health innovation is attracting growing investor and industry attention, but founders still face unique hurdles in raising capital, forming strategic alliances, and navigating exit opportunities. This panel will provide founders and executives with pragmatic strategies to build sustainable companies and capture long-term value in women's health.

Panelists:

Trish Costello, CEO & Founder, Portfolia; CEO Emeritus, Kauffman Fellows

Seema Kumar, CEO, Cure

Amy Millman, Founder, Springboard Enterprises

Liz Powell, Esq., MPH, Founder of Women's Health Advocates and G2G Consulting

WOMEN'S HEALTH ENTREPRENEURSHIP SUCCESS STORIES

2:15 The Economics of MedTech Innovation

Tracy MacNeal, President & CEO, Materna Medical

The global landscape of women's health continues to be marked by significant unmet needs, with progress often appearing slow and fragmented. This presentation examines the innovation cycle within the MedTech sector and its historical impact on women's health. It then explores the evolving landscape, highlighting key strategies for securing funding, navigating reimbursement pathways, and successfully launching transformative medical devices in today's healthcare environment.

2:25 The Future of Hormone Diagnostics

Amy Beckley, PhD, Founder & CEO, Proov

Proov invented the first and only FDA-cleared at-home PdG (progesterone metabolite) test in 2017. Since then, Proov's platform has expanded to measure all 4 reproductive hormones in urine. These tests are paired with pattern recognition and advanced analytics to truly understand how hormonal changes affect women's health and allow for personalized interventions to treat women quickly and effectively, even at home.

2:35 Swapping Science for Silence—Shifting How Society Values and Invests in Women's Health

Sabrina Martucci Johnson, President and CEO, Daré Bioscience

Daré Bioscience is a purpose-driven health biotech company focused solely on closing the gap between promising science and real solutions in women's health. Our targeted therapeutics are based in advanced science, backed by rigorous research and validated by peer review. From contraception to menopause, pelvic pain to fertility, vaginal health to infectious disease, we're closing critical gaps in care using science that serves her needs.

2:45 Hera Biotech—Diagnosing Endometriosis and Cervical Cancer

Somer Baburek, President & CEO, Hera Biotech

Hera delivers AI-powered, non-invasive diagnostics that bring clarity and timely decisions to women's health. Supporting endometriosis detection, cervical diagnosis, and clinical workflows, Hera replaces years of dismissal with trust, relief, and actionable confirmation for patients.

2:55 When Success Means Changing the System: Lessons from Building Evvy

Priyanka Jain, Co-Founder & CEO, Evvy

Evvy is unlocking precision women's healthcare through novel, overlooked female biomarkers—starting with the vaginal microbiome. Evvy is one of the fastest growing women's health companies in the US—enabling us to deliver innovative, high-quality care while scaling novel R&D to unlock a new, data-driven future in women's health. Evvy's Vaginal Health Test is the first at-home vaginal microbiome test to use metagenomic sequencing.

3:05 Refreshment Break in the Exhibit Hall

3:40 Chairperson's Remarks

Anula Jayasuriya, MD, PhD, Co-Founder & Managing Partner, Kidron Capital

Women's Health Venture and Innovation

Driving Innovation in Women's Health MedTech, Therapeutics, Diagnostics, and Digital Health



March 23-24, 2026

3:45 PANEL DISCUSSION: Commercialization Strategies for Women's Health

Moderator: Jodi Neuhauser, CEO & Founder, 51&

Explore how innovators are bringing groundbreaking women's health solutions to market. This panel will discuss effective commercialization strategies—from navigating regulatory and reimbursement landscapes to building partnerships, securing investment, and scaling access. Hear from industry leaders driving growth, adoption, and impact across the rapidly expanding women's health ecosystem.

Panelists:

Kristine Cecchetti Homovich, Senior Product Manager, Women's Health Strategy, Evernorth

Stefanie Diaz, Principal, Innovation and Venture Strategy, Catalyst by Wellstar

Eric Dy, PhD, Co-Founder & CEO, Bloomlife

Ikram Guerd, General Manager US, CMO, Aspivix

Candace Nagaraja, Managing Director and Partner, Women's Health Lead, L.E.K. Consulting

Rachel Braun Scherl, Co-Founder & Managing Partner, SPARK Solutions for Growth

4:30 PANEL DISCUSSION: Women's Health Therapeutics: Innovation, Funding, and Development Strategies

Moderator: Anula Jayasuriya, MD, PhD, Co-Founder & Managing Partner, Kidron Capital

Examine the rapidly evolving landscape of women's health therapeutics—from breakthrough discoveries to successful commercialization. This panel will explore innovation pipelines, investment trends, and strategic partnerships driving progress. Hear leaders discuss how targeted therapies and smart funding approaches are accelerating development and reshaping the future of women's health.

Panelists:

Angelika Fretzen, PhD, MBA, COO & Technology Translation Director, Wyss Institute, Harvard University

Elizabeth Garner, MD, MPH, CEO, SeNa Therapeutics

Linda Greub, Managing Partner, Avestria Ventures

Sabrina Martucci Johnson, President and CEO, Daré Bioscience

5:15 Welcome Reception in the Exhibit Hall

6:15 Close of Day

TUESDAY, MARCH 24

8:00 am Registration Open

8:00 BREAKFAST PANEL DISCUSSION: Capital to Commercial: The Women's Health BIOTECH Ecosystem

Moderator: Michele M. Oshman, Chief Patient Advocate, Senior Vice President, Alliance Development, Biotechnology Innovation Organization (BIO)

Join us for a breakfast discussion with leaders across the biotechnology continuum. From raising funds to commercial launch and market access, our speakers will discuss their unique perspectives and roles in advancing women's health.

Panelists:

Sabrina Martucci Johnson, President and CEO, Daré Bioscience

LaToya Wilson, Managing Director, Global Co-Head of Inclusive & Sustainable Ventures, Morgan Stanley

8:30 Transition to Sessions

8:35 PANEL DISCUSSION: Redefining Women's Health Through MedTech

Moderator: Nada O. Hanafi, MSc, MPH, Founder & Manager, MedTech Strategy Advisors, LLC; Co-Founder, MedTech Color; Co-Founder, Women's Health Advocates

Explore how MedTech is transforming women's health through cutting-edge devices, diagnostics, and digital solutions. This panel will highlight innovations addressing unmet needs across reproductive, maternal, and chronic care. Hear from industry leaders shaping a new era of precision, accessibility, and empowerment in women's health technology.

Panelists:

Megan Dover, Partner, Cross Border Impact Ventures

Anoushka Gungadin, CEO & Managing Director, HeraMED

Colby Holtshouse, President & CEO, May Health

Tracy MacNeal, President & CEO, Materna Medical

IN PERSON ONLY ROUNDTABLE DISCUSSIONS

9:20 Transition to Roundtable Discussions

9:30 Roundtable Discussions

Roundtable Discussions are informal, moderated discussions, allowing participants to exchange ideas and experiences and develop future collaborations around a focused topic. Each discussion will be led by a facilitator(s) who keeps the discussion on track and the group engaged. To get the most out of this format, please come prepared to share examples from your work, be a part of a collective, problem-solving session, and participate in active idea sharing. Please visit the Roundtable Discussions page on the conference website for a complete listing of topics and descriptions.

IN-PERSON ONLY ROUNDTABLE: The New Wave: How AI is Driving Women's Health Innovation

Imen Maaroufi Clark, Founder & CEO, Prickly Pear Health

IN-PERSON ONLY ROUNDTABLE: Rebuilding Credibility: The Currency of Trust in Women's Health Innovation

Denise Bronner, PhD, Founder & CEO, Empactful Ventures

- How credibility can and should be rebuilt as a core value driver for women's health innovation

- What measurable trust looks like in both scientific validation and investor diligence

- How communities assess legitimacy

- How founders and funders can co-create trust-based models that strengthen engagement, adherence, and long-term market sustainability

IN-PERSON ONLY ROUNDTABLE: Actionable Strategies for Overcoming Translational Hurdles in Women's Health Innovation

Sophia Ononye, PhD, MPH, MBA, Founder & CEO, The Sophia Consulting Firm

IN-PERSON ONLY ROUNDTABLE: Closing Gaps in Women's Health with Policy & Advocacy

Liz Powell, Esq., MPH, Founder of Women's Health Advocates and G2G Consulting

- Policies impacting women's health

- How to shape the process

- What to expect in 2026

10:00 Coffee Break in the Exhibit Hall

10:35 Chairperson's Remarks

Bethany Corbin, Co-Founder & CEO, FemInnovation

10:40 PANEL DISCUSSION: Digital Health and AI Enabling Women's Health Innovation

Moderator: Bethany Corbin, Co-Founder & CEO, FemInnovation

Learn how digital health and AI are accelerating breakthroughs in women's health. This panel will examine data-driven platforms, predictive algorithms, and virtual care models that improve diagnosis, treatment, and access. Experts will discuss how technology is closing knowledge gaps and delivering more personalized, equitable care for women worldwide.

Panelists:

Mark Amouzgar, Co-Founder & CEO, March Health

Lauren Cantor Wright, Principal, Yosemite

Patricia Geli, PhD, Co-Founder & Managing Partner, C10 Labs

Ann Holder, CEO & Founder, Marani Health

Chevon Rariy, MD, Chief Clinical Innovation Officer, Visana Health

FEMTECH INNOVATION SHOWCASE

11:20 Bloomlife: Redesigning Maternal Care Delivery for High-Risk Pregnancies

Eric Dy, PhD, Co-Founder & CEO, Bloomlife

Women's Health Venture and Innovation

Driving Innovation in Women's Health MedTech, Therapeutics, Diagnostics, and Digital Health



March 23-24, 2026

Over the past several decades there has been a significant increase in the rates of high-risk pregnancies requiring greater clinical care. At the same time, we have a growing shortage of maternal-healthcare providers, creating barriers to care for women throughout the US. There is an urgent need to redesign care delivery to ensure the highest-risk patients get access to care to improve birth outcomes.

11:30 Digital Twins and Multi-Agent AI in Women's Health: Detect Earlier, Treat Smarter

Mark Amouzgar, Co-Founder & CEO, March Health

March Health uses AI to build next-generation healthcare tools, including digital twins and multi-agent systems, to reduce preventable errors and improve outcomes. Guided by a strong team of physicians and specialists, March Health delivers early detection and personalized care across conditions from women's health to cardiovascular disease, helping save lives and billions in wasted healthcare costs.

11:40 A Retrospective, Claims-Based Evaluation of Total Cost of Care at Visana Health, a Virtual Women's Health Clinic

Chevon Rariy, MD, Chief Clinical Innovation Officer, Visana Health

We conducted a retrospective, propensity score-matched cohort study using commercial claims data to evaluate the effectiveness of Visana Health, a comprehensive virtual women's health care and navigation model (600 participants; 2,941 controls). Over six months, enrollment was associated with a \$3,429 reduction in total allowed costs per member (P=0.02), driven by decreased facility, professional, and gynecologic spending, alongside reduced inpatient and emergency department utilization.

11:50 Do You Have the Audacity to Prove the Experts Wrong?

Robert Bunn, CEO & Founder, Ultrasound AI

Preterm birth drives infant morbidity, yet current tools rarely warn early enough. In this talk, Robert Bunn, founder of Ultrasound AI, shows how prenatal ultrasound becomes a predictive signal with AI to estimate delivery timing and flag preterm risk weeks earlier. The approach requires no new equipment or workflow, enabling low-cost deployment. Bunn outlines the concept, clinical validation plan, and partnerships needed to translate prediction into prevention.

12:00 pm Company Spotlight: Ananya Health

Anu Parvatiyar, CEO, Ananya Health

Ananya Health is a medical device company building a platform to freeze and destroy abnormal tissue before it becomes cervical cancer. By removing the need for consumable cryogen, the platform delivers standard-of-care outcomes at a fraction of the cost of traditional cryoablation and enables providers at all levels of care to treat precancerous lesions. The Ananya Health team has five decades of medical device experience from concept to commercialization.

12:10 Afterthought to Architecture: Women's Health Is Powering the Future Healthcare Economy

Lisa Marceau, MPH, Founder & CEO, Joyuus; Founder & President, Alpha Millennial Health

Women's health has been ignored or narrowly defined as reproductive health. That framing is being challenged, and women are driving the change. Women's health represents the most powerful platform for predictive, longitudinal, and integrated healthcare innovation. This talk reframes women's health as infrastructure connecting market forces, emerging technology, and the healthcare economy. Attendees will gain perspective on where value is being created in healthcare, and why women are driving it.

12:20 Talk Title to be Announced

Rashmi Raghavendra, CEO, Dionysus Healthcare

12:30 Presentation to be Announced

12:40 Transition to Lunch

12:50 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:20 Refreshment Break in the Exhibit Hall

2:00 Chairperson's Remarks

Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University

2:05 PANEL DISCUSSION: Innovation in Menopause and Aging Care

Moderator: Claire Gill, Founder & President, National Menopause Foundation

The landscape of women's midlife health is undergoing a revolutionary transformation. This panel will delve into the evolving funding ecosystem for women's health innovations and address systemic barriers and opportunities across multiple sectors. With over one billion women globally expected to be in menopause by 2030, this session explores the potential to transform how society supports women during this critical life transition and beyond.

Panelists:

Rachel Butler, President, Catalytic Impact Foundation

Maria Gonzalez Blanch, Managing Partner, Crescent Ridge VC

Tarul Kode, PharmD, Vice President, Partnerships & Alliance Management, Persephoni Bio; Board Member, Advisor & Investor, Springboard Healthcare and Technology Council

Mitzi Krockover, MD, CEO, Woman Centered; Producer, Beyond the Paper Gown podcast; Managing Director, Golden Seeds; Co-Founder, Femtech AZ

Jayne Morgan, MD, Vice President, Hello Heart

2:45 PANEL DISCUSSION: Redefining Women's Health: Diagnostics, Data & Disruption

Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University

Diagnostics are rewriting the rules of engagement in women's health from cancer screening to period tracking and everything in between. This provocative panel dives into the technologies transforming how we detect, monitor, and manage conditions across the lifespan—from reproductive health to chronic disease. We'll explore how at-home testing and digital tools are unlocking earlier insights, enabling data-driven care, and powering a new generation of women-centered solutions.

Panelists:

Sofiat Akinola, Director, Health Policy and External Affairs, Roche Diagnostics Solutions

Farideh Bischoff, PhD, CMO, Global Head of Diagnostics, Heranova Lifesciences, Inc.

Priyanka Jain, Co-Founder & CEO, Evvy

Neha Kumar, Global Commercial Precision Medicine Strategy, Johnson & Johnson

DIAGNOSTICS INNOVATION SHOWCASE

3:25 Ending the Diagnostic Odyssey: AI-Enabled Mechanostics to Predict, Treat, and Prevent Complex Diseases Affecting Women's Health

Steve Gardner, PhD, CEO and Co-Founder, PrecisionLife

Women with chronic, under-researched diseases such as endometriosis face a diagnostic and therapeutic landscape that is delayed, invasive, and often ineffective. PrecisionLife is transforming this paradigm. Our combinatorial analytics and AI platform has uncovered previously invisible patterns of genetic risk and disease mechanisms across large-scale population data. We've used these insights to develop a new class of diagnostic tools called mechanostics – non-invasive, highly predictive tests that identify underlying drivers.

3:35 Continuous Hormone Monitor Empowering Women's Health

Uroš Kuzmanovic, PhD, CEO & Founder, BioSens8

BioSens8 is engineering a live data stream of our health state. Sensing a multitude of biomarkers continuously and in real-time with novel wearables will open the door to health ownership, personalized medicine, and proactive, data-driven decisions. One of BioSens8's first products is a continuous hormone monitor for female sex hormones designed to empower women with unprecedented insight and control over their health.

3:45 From Period Care to Preventive Care: Innovations in Vaginal Diagnostics Designed and Validated by Women, for Women

Lindsey Liebler, Head, US Commercial Strategy, Daye

This session will present clinical evidence supporting the use of medical-grade tampons as self-collection tools for vaginal diagnostics. Drawing from peer-reviewed studies published in journals including Clinical Microbiology and BMC Women's Health, Valentina Milanova will outline the comparative efficacy of tampon-based sampling versus clinician- and swab-based methods in detecting HPV, STIs, and vaginal microbiome imbalances. The talk will also address usability, patient acceptability, and implications for scaling decentralized diagnostic infrastructure.

3:55 Close of Conference

Women's Health: Drug Discovery to Novel Therapies

Where Innovation Meets Impact



Sponsored by

March 23-24, 2026

MONDAY, MARCH 23

7:30 am Registration Open and Morning Coffee

PLENARY KEYNOTE SESSION

8:30 Organizer's Welcome Remarks

Jason Green, Senior Conference Director, Cambridge Healthtech Institute

8:35 Chairperson's Remarks

Jen Radin, Principal, Deloitte

8:40 Keynote Introduction (Sponsorship Opportunity Available)

8:45 PANEL DISCUSSION: Fueling Women's Health with Science, Technology, Capital & Care

Moderator: Jen Radin, Principal, Deloitte

Women's health has gained momentum, but we need to capitalize on it in a meaningful way to make long-term, scalable, and sustainable progress. This keynote panel brings together the key stakeholders in venture, R&D, and healthcare to provide insights into the leading opportunities and challenges facing the field.

Panelists:

Michael Annichine, CEO, Magee-Womens Research Institute & Foundation

Cathy Friedman, Executive Venture Partner, Google Ventures

Jodi Neuhauser, CEO & Founder, 51&

Kathryn Rexrode, MD, MPH, Chief Academic Officer & Chief, Division of Women's Health, Brigham & Women's Hospital

Alice Zheng, MD, Partner, Foreground Capital

9:45 Grand Opening Coffee Break in the Exhibit Hall

WOMEN'S HEALTH: A CALL TO ACTION

10:25 Chairperson's Remarks

Wendy Young, PhD, Scientific Advisor & Board Director; Former Senior Vice President, Small Molecule Drug Discovery, Genentech

10:30 Drug Discovery & Women's Health: Where Are the Drugs?

Wendy Young, PhD, Scientific Advisor & Board Director; Former Senior Vice President, Small Molecule Drug Discovery, Genentech

Despite remarkable progress in medical science, women's healthcare continues to face critical gaps—nowhere more evident than in drug innovation. This talk will explore the current state of drug approvals for women's health, highlight substantial unmet medical needs, and discuss how funding dynamics shape innovation. It will highlight current trends in drug discovery and map out future directions for advancing innovation in women's health.

11:00 FEATURED PRESENTATION: Can We Put an End to Debilitating Morning Sickness?

Marlena Fejzo, PhD, Assistant Professor, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California; 2024 Time Women of the Year

Most pregnancies are affected by morning sickness, but 14% of pregnancies have severe symptoms that can be prolonged and debilitating and are associated with increased risk for adverse outcomes. Recently, we found the main determinant of severity of nausea and vomiting of pregnancy is sensitivity to the emetogenic hormone GDF15 produced by the placenta. The discovery of this causal mechanism has introduced new ways to prevent and treat it.

11:30 Sponsored Presentation (Opportunity Available)

12:00 pm Transition to Lunch

12:10 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:40 Session Break

ADVANCES IN TREATING CANCERS IN WOMEN

1:30 Chairperson's Remarks

Sarah Temkin, MD, Senior Director, Early Detection, American Cancer Society

1:35 Advances in Treating Cancer in Women

Sarah Temkin, MD, Senior Director, Early Detection, American Cancer Society
Unique sex-specific biological, hormonal, and genetic factors influence cancer risk, progression, and treatment response in women, yet these differences are often underrepresented in research and clinical development. This session will explore cutting-edge oncology tailored to women, including novel biomarkers and targeted therapies that will improve cancer outcomes for women.

2:05 A New Small Molecule Drug for Improving Women's Cancer Therapy

Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics; Dean for Translational Science and External Affairs, City of Hope National Medical Center

Proliferating cell nuclear antigen (PCNA) plays an essential role in regulating DNA synthesis and repair and is indispensable to cancer cell growth and survival. It represents an attractive molecular target to develop broad-spectrum anti-cancer agents. By targeting a cancer specific domain of PCNA, we identified a novel compound, AOH1996, which selectively kills cancer cells without any significant toxicity to a broad range of non-malignant cells. AOH1996 is in clinical trials.

2:35 The Discovery of Giredestrant for Breast Cancer

Gina Wang, PhD, Senior Director & Distinguished Scientist, Genentech Inc.
Giredestrant, a full ERa antagonist and degrader, has undergone multiple Phase III clinical trials for patients at various stages of breast cancer. The discovery and development of giredestrant will be shared to inspire further groundbreaking research aimed at helping patients in need.

3:05 Refreshment Break in the Exhibit Hall

CHANGEMAKERS: DRIVING INNOVATIVE THERAPIES

3:40 Chairpersons' Remarks

Tracy Dooley, MD, Partner, Avestria Ventures

Wendy Young, PhD, Scientific Advisor & Board Director; Former Senior Vice President, Small Molecule Drug Discovery, Genentech

3:45 Women's Health as a Discovery Engine: New Drug Targets for Preeclampsia and Glioblastoma

Megan Matthews, PhD, Assistant Professor, Department of Chemistry, University of Pennsylvania

Women's health, particularly life-threatening pregnancy disorders such as preeclampsia, remains profoundly underserved despite its central role in human life. I will present a chemoproteomic drug de-orphanization strategy using activity-based protein profiling to uncover the true targets of existing medicines. Remarkably, the stress-response pathways and druggable biology revealed in (pre)eclampsia also expose new therapeutic strategies and lead molecules for treating lethal brain cancers, including glioblastoma.

4:00 A Revolutionary Targeted Approach to Estrogen Deficiency Syndrome (EDS)

Yael Schwartz, PhD, President & CEO, Or Genix Therapeutics Inc.

EDS is characterized by marked changes to the urogenital region and all epithelial surfaces. Within 5 years post-menopause, the vagina and other epithelial surfaces lose more than 40% in thickness and elasticity, causing drying, itching, and inflammation. ORX-102 is a safe and effective alternative to currently marketed estrogens for long-term use even in women for whom estradiol and estriol are contraindicated.

4:15 Looking beyond Inflammation: A New Approach to Endometriosis Therapy

Aritro Sen, PhD, Co-Founder & CSO, Maip Therapeutics Inc.

Endometriosis affects >10% of reproductive-aged women. Most patients experience severe pain from abnormally intense and prolonged menstrual contractions, 2-3x more than non-menstrual pelvic-pain. Excessive uterine contractions and fibrosis are key drivers of this pain, yet no therapies in development specifically target these mechanisms. This presentation underscores a paradigm shift from targeting inflammation, to a new approach: directly addressing uterine hypercontractility and fibrosis in a non-hormonal fashion for endometriosis treatment.

Women's Health: Drug Discovery to Novel Therapies

Where Innovation Meets Impact

Sponsored by 

March 23-24, 2026

4:30 Next-Generation Therapies for Women's Health: Engineering Cell Therapy Platforms to Treat Endometriosis

Bishwas Shrestha, PhD, Co-Founder & CEO, Adjuva Bio Inc.

Adjuva Bio is developing next-generation cell therapies to treat endometriosis by targeting the fibrotic and inflammatory microenvironment that drives the disease. Our engineered cells are designed for precision targeting and localized immunomodulation to reduce inflammation. This presentation will highlight our therapeutic strategy, early preclinical data, and the broader potential of cell-based platforms to address major unmet needs in women's health.

4:45 Botulinum Toxin as a Novel Therapy for Major Depressive Disorder (MDD)

Dan Radecki, PhD, President & Head, Clinical R&D, Object Pharma Inc.

This talk will focus on the use of botulinum toxin as a novel therapy for major depressive disorder (MDD). Multiple controlled clinical trials have established the efficacy of this therapy in patients with moderate to severe MDD. Discussion will include the unique value drivers of this therapy, particularly for females, as well as the proposed biological mechanisms behind its efficacy.

5:00 A Botanical Approach to Non-Hormonal Women's Health Therapeutics

Sue McKinney, Founder & CEO, Altin Biosciences

The FDA's Botanical Drug Guidance offers drug developers a regulatory pathway to approval for plant-based medicines. Plants are sophisticated chemical manufacturing environments and hold therapeutic promise for a multitude of conditions. Altin Biosciences is pursuing a novel botanical therapeutic for the non-hormonal treatment of uterine fibroids. Learn about the regulatory pathway for botanicals, myths, challenges and opportunities.

5:15 Welcome Reception in the Exhibit Hall

6:15 Close of Day

TUESDAY, MARCH 24

8:00 am Registration Open

8:00 BREAKFAST PANEL DISCUSSION: Capital to Commercial: The Women's Health BIOTECH Ecosystem

Moderator: Michele M. Oshman, Chief Patient Advocate, Senior Vice President, Alliance Development, Biotechnology Innovation Organization (BIO)

Join us for a breakfast discussion with leaders across the biotechnology continuum. From raising funds to commercial launch and market access, our speakers will discuss their unique perspectives and roles in advancing women's health.

Panelists:

*Sabrina Martucci Johnson, President and CEO, Daré Bioscience
LaToya Wilson, Managing Director, Global Co-Head of Inclusive & Sustainable Ventures, Morgan Stanley*



8:30 Transition to Sessions

8:35 PANEL DISCUSSION: New Models for Advancing Therapeutics from Bench to Bedside

Moderator: Elizabeth Garner, MD, MPH, CEO, SeNa Therapeutics

Topics to be discussed:

- Awareness of translational opportunities and challenges that exist in getting ideas from preclinical to clinical
- Strategies and models being successfully employed to overcome some of the real-world therapeutic issues
- Leveraging data and AI/ML to accelerate progress
- Exploring pre-competitive partnerships to drive success

Panelists:

*Vanessa Braunstein, Senior Director, TuneLab AI Drug Discovery Platform, Eli Lilly & Co.
Angelika Fretzen, PhD, MBA, COO & Technology Translation Director, Wyss Institute, Harvard University
Andrea Olariu, MD, PhD, CEO, Medicines360
Janet Pregler, MD, Professor, Clinical Medicine, University of California at Los Angeles; Director, Iris Cantor-UCLA Women's Health Center
Judith Regensteiner, PhD, Distinguished Professor, Internal Medicine; Director, Ludeman Family Center for Women's Health Research, University of Colorado Denver*

IN PERSON ONLY ROUNDTABLE DISCUSSIONS

9:20 Transition to Roundtable Discussions

9:30 Roundtable Discussions

Roundtable Discussions are informal, moderated discussions, allowing participants to exchange ideas and experiences and develop future collaborations around a focused topic. Each discussion will be led by a facilitator(s) who keeps the discussion on track and the group engaged. To get the most out of this format, please come prepared to share examples from your work, be a part of a collective, problem-solving session, and participate in active idea sharing. Please visit the Roundtable Discussions page on the conference website for a complete listing of topics and descriptions.

IN-PERSON ONLY ROUNDTABLE: How to Effectively Leverage Technology to Accelerate Drug Development for Women's Health

*Petrina Kamyra, PhD, Global Head of AI Platforms & Vice President, Insilico Medicine; President, Insilico Medicine Canada
Caitlyn Krebs, Co-Founder & CEO, Nalu Bio
Ewa Lis, PhD, Founder & CEO, Koliber Biosciences
Nikki Simpson, Principal Investigator, In Vivo Pharmacology, PostEra*

IN-PERSON ONLY ROUNDTABLE: Key Learnings Going from Bench to the Clinic

*Marlena Fejzo, PhD, Assistant Professor, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California; 2024 Time Women of the Year
Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics; Dean for Translational Science and External Affairs, City of Hope National Medical Center
Aritro Sen, PhD, Co-Founder & CSO, MaipI Therapeutics Inc.*

IN-PERSON ONLY ROUNDTABLE: Bridging Preclinical and Clinical Data in Women's Health

*Michael Liebman, PhD, Managing Director, IPQ Analytics, LLC
Nisha Perez, ScD, MS, MSPM, Head of DMPK & Clinical Pharmacology, HotSpot Therapeutics
Sophie Zaaier, PhD, Principal Investigator, University of California Riverside*

10:00 Coffee Break in the Exhibit Hall

TECHNOLOGIES ACCELERATING WOMEN'S HEALTH

10:35 Chairperson's Remarks

Aritro Sen, PhD, Co-Founder & CSO, MaipI Therapeutics Inc.

10:40 Leveraging AI for the Discovery of Novel Targets and Repurposed Drugs to Address Diseases Implicated in Women's Health

Petrina Kamyra, PhD, Global Head of AI Platforms & Vice President, Insilico Medicine; President, Insilico Medicine Canada

There is a significant gap when it comes to understanding the underlying causes affecting women's health and funding for R&D. I will describe the work we did in collaboration with Gynae Solutions, the Buck Institute for Research on Aging, and the Chinese University of Hong Kong to identify novel targets implicated in immune pathways, as well as a drug being repurposed to address endometriosis.

11:10 AI-Driven Discovery of Next-Generation Oncology Therapeutics for Women's Healthcare

Lana Kulyk, PhD, Executive Director, Chemistry, Iambic Inc.

Iambic is advancing a pipeline of next-generation oncology therapeutics through its AI-driven drug discovery platform, with a strong focus on women's healthcare, particularly ovarian and breast cancer. This presentation highlights a HER2 inhibitor in a Phase 1/1b clinical trial, demonstrating exceptional selectivity, broad mutant coverage, and robust brain penetrance. Programs are powered by Iambic's ML models, including PropANE, Enchant, NeuralPLexer, integrated with high-throughput synthesis and screening to accelerate end-to-end discovery.

Women's Health: Drug Discovery to Novel Therapies

Where Innovation Meets Impact

Sponsored by 

March 23-24, 2026

11:40 Breaking Barriers in Women's Health through Drug Delivery Innovation

Sabrina Martucci Johnson, President and CEO, Daré Bioscience

Women are not just small men, and their health solutions shouldn't be scaled-down versions of male-centered models. Daré's novel drug-delivery technologies are designed specifically for women and address the often-overlooked areas such as sexual and reproductive health that demand more targeted, thoughtful approaches to care.

12:10 pm Improving Female & Male Fertility Patient Experience with LHCGR Agonists

Nikki Simpson, Principal Investigator, In Vivo Pharmacology, PostEra

Luteinizing Hormone/Choriogonadotropin Receptor (LHCGR) is a critical regulator of fertility and necessary for follicle development and normal spermatogenesis. Loss of LHCGR activity leads to infertility. The injectable LHCGR agonist, hCG, is the current standard of care for females undergoing controlled ovarian stimulation and/or males with secondary hypogonadism. Using our machine learning platform, we identified potent, drug-like small-molecule LHCGR agonists with comparable efficacy to hCG in murine *in vivo* models.

12:40 Transition to Lunch

12:50 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:20 Refreshment Break in the Exhibit Hall

OVERCOMING TRANSLATIONAL HURDLES

2:00 Chairperson's Remarks

Charlene Bashore, PhD, Principal Scientist, Biochemistry, Merck

2:05 Precision Dosing for Her: Women and Clinical Blunders

Nisha Perez, ScD, MS, MSPM, Head of DMPK & Clinical Pharmacology, HotSpot Therapeutics

Persistent disparity in female drug pharmacokinetics and dosing leads to a "one-size-fits-all" approach, often based on male-centric data. This oversight causes suboptimal efficacy or increased adverse drug reactions in women. Examining historical clinical studies and drug approvals where female-specific data were inadequately considered is crucial for understanding these failures and informing appropriate drug-development and prescribing practices.

2:35 Using Personalized Predictive Models to Transform Discovery, Translation, and Access for Women

Andrea Olariu, MD, PhD, CEO, Medicines360

Personalized predictive models are transforming the landscape of women's health. By leveraging data-driven insights and AI-powered tools, researchers and clinicians can identify unique health patterns, accelerate biomedical discoveries, and tailor interventions to individual needs. We'll discuss how these models are being applied to close gaps in diagnosis and improve clinical trial representation. We'll highlight considerations, challenges, and translational opportunities that come with deploying predictive models in real-world settings.

3:05 PANEL DISCUSSION: Why Counting Women Isn't Enough: Rethinking Clinical Trials to Serve Women's Health

Moderator: Sophie Zaaijer, PhD, Principal Investigator, University of California Riverside

This panel explores how clinical trials must move beyond simply counting women to truly serve women's health. We explore: what if trials were designed differently from the ground up—using diagnostics that capture the rhythms of female biology, enrollment criteria that enable fair representation, and digital tools that reveal women's real-world experiences? The message is clear: rethinking trials across every stage unlocks stronger science and healthier futures.

Panelists:

Katie Baca-Motes, MBA, CEO, GSD Health Research

Michael Liebman, PhD, Managing Director, IPQ Analytics, LLC

Rashmi Raghavendra, CEO, Dionysus Healthcare

Kimberly Rosen, MD, Executive Director, Clinical Development, Organon

4:05 Close of Conference



Who You'll Meet:

By bringing together investors, startups, innovators, researchers, clinicians, advocates, and executives, HERS convenes a program and community as ambitious as its mission—to advance women's health, capital, and care.

Join us to bridge sectors across healthcare, align strategic thought with practical execution, and turn ideas into lasting impact for women's health. **You will meet:**

- **Investors and venture capitalists** fueling innovation across the ecosystem
- **Entrepreneurs and founders** building the next generation of women's health startups
- **Scientists and R&D leaders** advancing new drug targets and biomarkers
- **Clinicians and healthcare providers** redefining standards of care
- **Technologists and data innovators** applying AI and digital health tools
- **Payers and market-access experts** shaping new and comprehensive coverage models
- **Policy and advocacy leaders** advancing women's health on the national stage
- **Health-system executives** driving clinical integration and value-based care
- **Medical affairs and regulatory specialists** bridging science and implementation
- **Partners and collaborators** committed to transforming women's health

The Future of Women's Healthcare

Redefining Care, Revolutionizing Health Outcomes for Women



March 23-24, 2026

MONDAY, MARCH 23

7:30 am Registration Open and Morning Coffee

PLENARY KEYNOTE SESSION

8:30 Organizer's Welcome Remarks

Jason Green, Senior Conference Director, Cambridge Healthtech Institute

8:35 Chairperson's Remarks

Jen Radin, Principal, Deloitte

8:40 Keynote Introduction (Sponsorship Opportunity Available)

8:45 PANEL DISCUSSION: Fueling Women's Health with Science, Technology, Capital & Care

Moderator: Jen Radin, Principal, Deloitte

Women's health has gained momentum, but we need to capitalize on it in a meaningful way to make long-term, scalable, and sustainable progress. This keynote panel brings together the key stakeholders in venture, R&D, and healthcare to provide insights into the leading opportunities and challenges facing the field.

Panelists:

Michael Annichine, CEO, Magee-Womens Research Institute & Foundation

Cathy Friedman, Executive Venture Partner, Google Ventures

Jodi Neuhauser, CEO & Founder, 51&

Kathryn Rexrode, MD, MPH, Chief Academic Officer & Chief, Division of Women's Health, Brigham & Women's Hospital

Alice Zheng, MD, Partner, Foreground Capital

9:45 Grand Opening Coffee Break in the Exhibit Hall

THE FUTURE OF WOMEN'S HEALTHCARE

10:25 Chairperson's Remarks

Priya Bathija, Founder & CEO, Nyoo Health

10:30 PANEL DISCUSSION & OPEN Q&A: From Fragmented to Foundational—Reimagining the Future of Women's Healthcare

Moderator: Priya Bathija, Founder & CEO, Nyoo Health

• What are our current thoughts on where we are on the journey of women's healthcare?

• What needs to change to shift the conversation around reimbursement of women's health?

• How is AI set to impact women's health specifically?

• At what point does Women's Health become just "health"?

• In a perfect world, what does women's healthcare look like?

Panelists:

Joanne Armstrong, Vice President & Chief Medical Officer, CVS Health

Jill Foley, MD, Chair, Women's Health Service Line, Sutter Health

Carlos Roberts, Vice President & Chief Medical Officer, Women's & Children's Service Line, Wellspan Health

Megan Tirone, Vice President & Chief Medical Officer, Women's Services, BayCare Health System

11:30 Sponsored Presentation (Opportunity Available)

12:00 pm Transition to Lunch

12:10 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:40 Session Break

OVERCOMING BARRIERS AND FILLING THE GAPS FOR ACCESS TO CARE

1:30 Chairperson's Remarks

Priya Bathija, Founder & CEO, Nyoo Health

1:35 The Overlooked Link between Endometriosis and Black Maternal Mortality

Calbeth C. Alaribe, OBGYN Hospitalist Physician Assistant; Health Equity Subject Matter Expert, Valley Perinatal Services

Black women face disproportionate risks of maternal mortality from hypertensive disorders of pregnancy, yet their experiences with endometriosis remain underexamined in research. This talk explores the overlooked intersection between endometriosis and preeclampsia/eclampsia, highlighting systemic gaps in U.S. studies and their consequences for Black maternal health. By reframing endometriosis beyond pain, this presentation calls for inclusive, equity-driven research to inform early-detection, clinical care, and policy aimed at reducing preventable maternal deaths.

2:05 PANEL DISCUSSION & OPEN Q&A: How Are We Moving the Needle to Provide Access to Care for All?

Moderator: Priya Bathija, Founder & CEO, Nyoo Health

• What are the major barriers and gaps in providing access to women's health?

• What approaches are working when it comes to improving access to care?

• How are we ensuring that our work provides access to care for all?

• How can we collaborate across the entire healthcare ecosystem to provide better access to women's healthcare?

• How are digital and virtual approaches helping us provide more access?

Panelists:

Indy Lane, MD, MBA, FACOG, Vice President, Women's Health Service Line, Allina Health

Lisa Pellerin, System Vice President, Women's Services, Ochsner Health

Lori-Ann Satran, Associate Vice President, Women, Infants, and Children, Honor Health

Nadine Walker, Executive Director, Women's Services, AdventHealth

3:05 Refreshment Break in the Exhibit Hall

CASE-STUDY SHOWCASE

3:40 Chairperson's Remarks

Priya Bathija, Founder & CEO, Nyoo Health

3:45 Case-Study Presentation: Leveraging Technology to Improve Outcomes and Decentralize Care in the "Fourth Trimester"

Ukachi Emeruwa, Assistant Professor, Women's Reproductive Health Research Scholar, UC San Diego Health

• The current and future opportunities in enhancing care in the fourth trimester

• A look at research that is utilizing wearable tech to help provide more end-to-end care

• What are the future goals of this research?

4:15 Case-Study Presentation: Tackling Maternal Health, Improving Disparities

Dawnette Lewis, MD, Director, Center for Maternal Health, Northwell Health

Northwell Health is the largest health system in the Northeast, and the most diverse. Dawnette Lewis, MD, OBGYN, maternal fetal medicine specialist, and director of Northwell's Center for Maternal Health details efforts to improve overall maternal health, particularly to close the disparity gaps facing women of color.

4:45 Case-Study Presentation: Designed for Her: How AI Implementation Can Level the Playing Field for Women's Health

Ami Bhatt, Chief Innovation Officer, American College of Cardiology

We will critically analyze why the promise of AI in healthcare continues to fall short, and how we can flip the script by making women clinicians, entrepreneurs, investors, and patients the co-architects of tech solutions. From biased algorithms and workflow mismatches to fiscal investment and marketing, this session focuses on building better systems starting with the end goal of equitable care in mind.

5:15 Welcome Reception in the Exhibit Hall

6:15 Close of Day

The Future of Women's Healthcare

Redefining Care, Revolutionizing Health Outcomes for Women

March 23-24, 2026

TUESDAY, MARCH 24

8:00 am Registration Open

8:00 BREAKFAST PANEL DISCUSSION: Capital to Commercial: The Women's Health BIotech Ecosystem

Moderator: Michele M. Oshman, Chief Patient Advocate, Senior Vice President, Alliance Development, Biotechnology Innovation Organization (BIO)

Join us for a breakfast discussion with leaders across the biotechnology continuum. From raising funds to commercial launch and market access, our speakers will discuss their unique perspectives and roles in advancing women's health.

Panelists:

Sabrina Martucci Johnson, President and CEO, Daré Bioscience
LaToya Wilson, Managing Director, Global Co-Head of Inclusive & Sustainable Ventures, Morgan Stanley



8:30 Transition to Sessions

8:35 Presentation to be Announced

IN PERSON ONLY ROUNDTABLE DISCUSSIONS

9:20 Transition to Roundtable Discussions

9:30 Roundtable Discussions

Roundtable Discussions are informal, moderated discussions, allowing participants to exchange ideas and experiences and develop future collaborations around a focused topic. Each discussion will be led by a facilitator(s) who keeps the discussion on track and the group engaged. To get the most out of this format, please come prepared to share examples from your work, be a part of a collective, problem-solving session, and participate in active idea sharing. Please visit the Roundtable Discussions page on the conference website for a complete listing of topics and descriptions.

IN-PERSON ONLY ROUNDTABLES: Future of Women's Healthcare

Vasanta Pundarika, CEO & Founder, Lotuspring

In these dynamic discussion-led sessions, have more informal discussions around the current opportunities and challenges for the key conditions in women's health.

Share and exchange ideas around crucial areas and leave with new knowledge and connections.

Topics include:

- 1) Fertility in Focus
- 2) Maternal Meet-Up
- 3) Menopause Mindshare

10:00 Coffee Break in the Exhibit Hall

CASE-STUDY SHOWCASE

10:35 Chairperson's Remarks

Vasanta Pundarika, CEO & Founder, Lotuspring

10:40 Case-Study Presentation: Leveraging Digital Strategies to Improve Postpartum Care and Long- Term Cardiovascular Health Following Hypertensive Pregnancies

Amy Sarma, MD, Director, Women's Heart Health Program, Massachusetts General Hospital

Hypertensive disorders of pregnancy affect an increasing number of women in the United States and increase the risk of both postpartum morbidity and mortality as well as later-life cardiovascular disease. In this talk, I will cover the current landscape of digital solutions to improve the care of postpartum patients as well as future opportunities.

11:10 Case-Study Presentation: Expanding Access and Excellence in Urogynecology: Building a Comprehensive Care Model

Tanaz Ferzandi, MD, MBA, MA, Vice Chief of Staff & Service Line Chief of Obstetrics & Gynecology, Keck Hospital of USC

This session will explore strategies for providing wrap-around care that addresses the full spectrum of patient needs, while advancing the growth and capabilities of the urogynecology service line. Attendees will gain insights into operational best practices, multidisciplinary collaboration, and opportunities to expand into complementary areas of women's health.

11:40 Case-Study Presentation: Knitting Together the Women's Healthcare Ecosystem to Revolutionize Women's Health

Carol Huffman, Vice President Clinical Innovation & Implementation, MVP Health Care

- A look at how innovative partnerships are building wrap-around healthcare around patients
- Introducing novel aspects of this work such as building in care for the father/co-parent, data-sharing, and more
- What is the path forward to scale this work?

12:10 pm Sponsored Presentation (Opportunity Available)

12:40 Transition to Lunch

12:50 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:20 Refreshment Break in the Exhibit Hall

IMPROVING OUTCOMES BY CONNECTING WOMEN'S HEALTH ACROSS HEALTHCARE

2:00 Chairperson's Remarks

Vasanta Pundarika, CEO & Founder, Lotuspring

2:05 Case-Study Presentation: Designing & Building a Patient-First Women's Hospital

Jason Melillo, Vice President, Women's Clinical Services, OhioHealth
Kristina Stuecher, Vice President, OhioHealth, Women's Center, OhioHealth

- A look at what women say they are looking for from their care providers
- How have we incorporated this information into the design and building of our new women's health hospital
- What is the vision for the future of women's health at our organization?

2:35 PANEL DISCUSSION & OPEN Q&A: Next Steps in Collaborating and Scaling Work Internally and Externally to Improve Patient Outcomes Moving Forward

Moderator: Vasanta Pundarika, CEO & Founder, Lotuspring

- What are the key internal and external working groups that are moving the needle on patient outcomes?
- How are organizations structuring their women's health teams? What is working, what is not working?
- Which methods are working when connecting women's health specialists and other healthcare specialists at scale?
- How are we leveraging AI to improve patient outcomes?
- How can we continue to collaborate across women's health to improve patient outcomes?

Panelists:

Priya Bathija, Founder & CEO, Nyoo Health

Amy Foundos, Director, Clinical Services, Women's & Newborn Care, Scripps Health

Debra Wickman, Director, Female Sexual Medicine, Banner University Health System

3:35 Close of Conference

Sponsorship Opportunities

Sponsorship Level

Exhibit Hall & Delegate Passes

Thought Leadership & Branding

PREMIER SPONSORSHIP

- One 8x10 space (includes table, 2 chairs & wastebasket)
- Three (3) main conference registrations for your team (excludes short courses and symposia)
- One (1) main conference registration for your speaker
- Onsite signage designating your company as a premier sponsor

- 30-minute presentation to all session attendees as part of the main conference program or over lunch
- Enhanced Branding: Please choose 1 of the following branding opportunities (based on availability):

Enhanced Branding:

- o Exhibit Hall Reception
- o Exhibit Hall Break Sponsor
- o Branded item such as pens, lip balm, or other relevant products
- o Tote Bags
- o Lanyards
- o Roundtable Moderator
- Full contact information of all conference attendees (GDPR compliant)
- Post-conference attendee list for one-time usage through a third-party mail house (physical mailing)

CORPORATE SPONSOR: PRESENTATION

- One 8x10 space (includes table, 2 chairs & wastebasket)
- Two (2) main conference registrations for your team (excludes short courses and symposia)
- One (1) main conference registration for your speaker
- Two (2) exhibit-only registrations for your booth staff

- Includes one 15 or 30-minute presentation to all session attendees as part of the main conference program
- Talk promoted in the final conference brochure, event website, agenda and onsite signage
- Onsite signage designating your company as a corporate sponsor

CORPORATE SPONSOR: LUNCHEON PRESENTATION

- One 8x10 space (includes table, 2 chairs & wastebasket)
- Two (2) main conference registrations for your team (excludes access to short courses and symposia)
- One (1) main conference registration for your speaker
- Two (2) exhibit-only registrations for your booth staff

- Corporate Sponsor will have a 30-minute luncheon presentation including Q&A (track specific).
- CHI will provide lunch for track attendees onsite
- Talk promoted in the final conference brochure, event website, agenda and onsite signage
- Full contact information for all registered attendees to the track in which you are presenting (GDPR compliant)
- Onsite signage designating your company as a corporate sponsor
- Company literature table inside the session room

CORPORATE SUPPORT SPONSOR: BRANDING

- One 8x10 space (includes table, 2 chairs & wastebasket)
- Three (3) main conference registrations for your team (excludes short courses and symposia)
- One (1) main conference registration for your speaker
- Onsite signage designating your company as a premier sponsor

Branding – your choice of (select one):

- o Coffee/Refreshment Break Sponsorship
- o Literature Distribution – “Chair Drop” – specific to one program
- o Literature Distribution – “Tote Bag Insert” – all conference delegates
- o Digital Meterboard (Image will remain on screen for 15 seconds per loop)
- o One additional conference pass to the main conference program
- o Chairperson Role

CORPORATE SUPPORT SPONSORSHIP

- One 8x10 space (includes table, 2 chairs & wastebasket)
- Two (2) main conference registrations for your team (excludes short courses and symposia)
- One (1) main conference registration for your speaker
- Two (2) exhibit-only registrations for your booth staff

- Onsite signage designating your company as a corporate support sponsor
- Post-conference attendee list for one-time usage through a third-party mail house

CORPORATE SPONSOR: PLENARY KEYNOTE INTRO

- One 8x10 space (includes table, 2 chairs & wastebasket)
- Two (2) main conference registrations for your team (excludes short courses and symposia)
- One (1) main conference registration for your speaker
- Two (2) exhibit-only registrations for your booth staff

- Sponsor will send an executive from their company to deliver 5-minute introductory presentation during a plenary keynote session
- Onsite signage designating your company as a corporate sponsor

ONE-ON-ONE MEETINGS: CORPORATE SPONSORSHIP

- One 8x10 space (includes table, 2 chairs & wastebasket)
- Two (2) main conference registrations for your team (excludes short courses and symposia)
- Two (2) exhibit-only registrations for your booth staff
- Two (2) main conference registrations (excludes short courses and symposia)

- Your company will select invitees from the conference pre-registration list. CHI will set up **6-8 one-on-one meetings**, 15-20 minutes each with your TOP prospects and confirm appointment.
- Meeting space for one-on-one meetings
- Your company will select invitees from the conference pre-registration list
- CHI will place reminder cards in the badges of attendees onsite
- CHI will extend invitations, conduct follow-up and monitor responses
- Onsite signage designating your company as a corporate sponsor

To learn more about sponsorship and exhibit opportunities, please contact:



Companies A-K
Ilana Quigley

Sales Director
T: 857.636.2334
iquigley@healthtech.com



Companies L-Z
Kristin Skahan

Sr. Manager, Business Development
T: 781.429.9985
kskahan@healthtech.com

ALL SPONSORSHIP LEVELS INCLUDE:

- Onsite signage denoting sponsorship level
- Corporate logo on the conference proceedings
- Additional full conference registrations available at a discount for your staff (Limited to 5)
- 50-word company description in the conference materials
- Post conference attendee list for one-time usage through a third-party mail house (GDPR compliant)
- Promotion in post-conference email campaign sent to all attendees
- Corporate logo with link on the event website and conference materials
- Pre-conference attendee list for one-time usage through a third-party mail house
- Conference discount for your clients & prospects



CRO-VENDOR-TECH
CONSULTANCY-
SERVICES PROVIDER

PHARMA-BIOTECH-
MED DEVICE FINANCE
COMPANY

INVESTOR/BANKER-
HEALTHCARE PAYERS &
PROVIDERS-ACADEMIC-
GOVERNMENT SITE-
CBOS/501(C)(3)

INDIVIDUAL CONFERENCE PRICING

Includes access to all conferences. Plus, On-Demand access for one year

Early Bird Registration Rate until February 27, 2026	\$2,399	\$1,399	\$1,199
Standard Registration and Onsite	\$2,499	\$1,499	\$1,299

GROUP CONFERENCE PRICING

Includes access to all conferences. Plus, On-Demand access for one year

Early Bird Registration Rate until February 27, 2026	\$1,799	\$1,049	\$899
Standard Registration and Onsite	\$1,874	\$1,124	\$974

GROUP DISCOUNTS

Have your colleagues or entire team attend! Purchase a full-price registration, and participants from the same organization will receive a **25% discount** when registering through the Group Registration page. For more information on group discounts, contact [Juliet Nelson](#), 781-247-1813.

ALUMNI DISCOUNT—SAVE 15%

CHI appreciates your participation at our events. As a result of the great loyalty you have shown us, we are pleased to extend to you the exclusive opportunity to save an additional **15% off** the registration rate.

*Alumni, X, LinkedIn, Facebook, or any other promotional discounts cannot be combined.

How to Register: **HERSusa.com**

reg@healthtech.com | P: 781.972.5400 or Toll-free in the U.S. 888.999.6288

Please use
keycode **HERSPDF**
when registering!



Hotel & Travel

Conference Venue and Hotel:
Hilton San Diego Bayfront
1 Park Boulevard
San Diego, CA 92101

Discounted Room Rate: \$359

Discounted Room Rate Cut-off Date: February 20, 2026

For hotel reservations, please visit the [TRAVEL PAGE](#) »